leadf
logo-loader
viewFSD Pharma

FSD Pharma says first patient dosed in Phase 2a clinical trial of FSD201 to treat hospitalized patients with COVID-19

The trial involves 352 patients to assess the efficacy and safety of FSD201 together with standard of care (SOC) compared to SOC alone

covid-19
The trial's primary objective is to determine whether FSD201 plus SOC provides a significant improvement in the status of patients (shorter time to symptom relief)

FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE) announced Tuesday the dosing of the first patient in its Phase 2a clinical trial of FSD201 for the treatment of hospitalized patients with COVID-19.

The trial is a randomized, controlled, double-blind, multicenter study, conducted on 352 patients to assess the efficacy and safety of FSD201 dosed at 600 milligrams (mg) or 1200mg twice-daily, together with standard of care (SOC) compared to SOC alone in hospitalized patients with documented COVID-19 disease. Eligible patients will present symptoms consistent with influenza/coronavirus signs (fever, dry cough, malaise, difficulty breathing).

In a statement, the company said the primary objective of the trial is to determine whether FSD201 plus SOC provides a significant improvement in the clinical status of patients (shorter time to symptom relief). 

READ: FSD Pharma wins FDA nod to begin Phase 2 clinical trial for its lead drug micro-PEA to treat coronavirus patients

Secondary objectives include determining whether FSD201 plus SOC demonstrates additional benefit in terms of safety, objective assessments such as length of time to normalization of fever, length of time to improvement in oxygen saturation, and length of time to clinical progression, including the time to mechanical ventilation or hospitalization, and length of hospital stay.

Known as ultra-micronized PEA, the drug is a naturally occurring fatty acid similar to an endocannabinoid, one of a suite of molecules found in cannabis that targets endocannabinoid receptors in the human body.

FSD-201 works by reducing lung inflammation caused by small proteins called cytokines that are central to the “cytokine storm” phenomenon, where the body attacks its own cells rather than just fighting off the COVID-19 disease caused by the SARS-CoV-2 virus. 

This so-called storm of an "over-exuberant" inflammatory response causes acute lung injury in hospitalized patients and is a leading cause of death for those infected.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

 

Quick facts: FSD Pharma

Price: 2.7 CAD

CSE:HUGE
Market: CSE
Market Cap: $51.74 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of FSD Pharma named herein, including the promotion by the Company of FSD Pharma in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

FSD Pharma fully funded to continue progress on its Phase 2 study on...

FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE.CN) CEO Raza Bokhari tells Proactive the biopharma group is fully funded to continue progress on its Phase 2 study to treat hospitalized coronavirus patients. Bokhari says its most recent fundraising gives the firm $9.5M to conduct the trial, which will...

on 11/04/2020

2 min read